More about

Fred Hutchinson

News
September 04, 2019
4 min read
Save

Clinical trial participation studies show possible survival benefit, misconceptions of patient concerns

Clinical trial participation studies show possible survival benefit, misconceptions of patient concerns

Participation in therapeutic drug trials appeared associated with longer OS among patients with non-small cell lung cancer, according to results of a retrospective study scheduled for presentation at Quality Care Symposium.

News
August 10, 2019
1 min read
Save

NCI grant to fund research into aggressive pancreatic cancer subtype

NCI grant to fund research into aggressive pancreatic cancer subtype

Sita Kugel, PhD, a scientist at Fred Hutchinson Cancer Research Center, received an NCI award that will fund her laboratory’s research into an aggressive form of pancreatic cancer.

News
August 09, 2019
4 min read
Save

Are there feasible alternatives to BCG for the effective treatment of bladder cancer?

Are there feasible alternatives to BCG for the effective treatment of bladder cancer?

Click here to read the Cover Story, “BCG: a real-world example of health care rationing.”

News
July 25, 2019
2 min read
Save

HemOnc Today honors Next Gen Innovators

HemOnc Today held a reception at ASCO Annual Meeting to honor its third class of Next Gen Innovators.

News
July 15, 2019
2 min read
Save

ASH announces award recipients

Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition, scheduled for Dec. 7-10 in Orlando, Florida.

News
June 06, 2019
3 min read
Save

Pembrolizumab demonstrates acceptable safety among patients with cancer and HIV

Pembrolizumab demonstrates acceptable safety among patients with cancer and HIV

CHICAGO — Pembrolizumab exhibited an acceptable safety profile among patients with cancer and HIV who had more than 100 CD4 cells/µL and received antiretroviral therapy, according to results of a phase 1 trial presented at ASCO Annual Meeting.

News
April 22, 2019
3 min watch
Save

VIDEO: ‘Huge effort’ underway to identify biomarkers in urothelial cancer

VIDEO: ‘Huge effort’ underway to identify biomarkers in urothelial cancer

NEW YORK — Petros Grivas, MD, PhD, medical oncologist and clinical director of the genitourinary cancers program at University of Washington and Fred Hutchinson Cancer Research Center, presented two talks at HemOnc Today New York.

News
April 10, 2019
5 min read
Save

Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?

Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?

Click here to read the Cover Story, “Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’.”

News
April 10, 2019
15 min read
Save

Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’

Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’

The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most common adult lymphoproliferative disorder in the U.S.

News
March 22, 2019
3 min read
Save

First-line treatment for metastatic renal cell carcinoma evolving, but biomarkers still lacking

NEW YORK — First-line treatment of patients with metastatic renal cell carcinoma has evolved considerably in the past 18 months with FDA approval of cabozantinib monotherapy and the combination of ipilimumab and nivolumab.

View more